Mike Bassett is a journalist who writes for MedPage Today, covering a wide range of medical and healthcare topics. His articles provide in-depth analysis and reporting on issues such as drug overdoses, cancer diagnoses, clinical trials, and advancements in medical treatments. Mike's work has also appeared in Knowledia, further showcasing his expertise in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Mike Bassett's articles predominantly focus on healthcare and pharmaceuticals, with a particular emphasis on cancer research, medical treatments, clinical trials, and oncology. His coverage heavily relies on data citations.
When reaching out to Mike Bassett, consider providing data-driven insights or expert commentary related to the latest developments in cancer research and medical treatments. Pitches should be backed by credible data sources and provide valuable analysis or interpretation of scientific findings within these areas of interest.
Given his broad spectrum of topics covered under healthcare & pharmaceuticals, pitches must offer unique perspectives supported by reliable scientific evidence or recent breakthroughs in the field.
This information evolves through artificial intelligence and human feedback. Improve this profile .
— USPSTF screening recommendations, broader indication for ribociclib, OS win for pembrolizumab
By: Mike Bassett
— Improvements seen in pain, neuropathy, and cognitive function Symptom screening improved symptom scores among children with cancer compared with usual care, two randomized trials showed.
By: Mike , Bassett
But absence of significant OS benefit raises questions about long-term benefit, expert says
— Results "signal a paradigm shift," expert says Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery significantly
— Improved markers of disease severity as well in small trial of steroid-ineligible patients
By: Mike Bassett
— 78% of patients in prospective study had tumor downstaging with immune checkpoint inhibitors
— A greater proportion of women on the waitlist and undergoing transplant since adoption
By: Mike Bassett
— Notably, tapering reduced the risk of infection compared with a fixed dose
— First positive phase III study for a GLP-1 agonist in chronic liver disease
— Liver fat reductions were sustained for up to a year with the thyroid hormone receptor agonist
(833) 317-6278 
